NR Sales Hit $129M: What Niagen Bioscience's 30% Growth Signals About the NAD+ Market

Nicotinamide riboside (NR) was, until recently, a supplement category known primarily to longevity researchers and early-adopter biohackers. The 2025 financials from Niagen Bioscience — the company that markets Niagen, the original commercially available NR product — suggest that window has closed. A 30% year-over-year revenue increase to $129.4 million, alongside a 103% jump in net income to $17.4 million, describes a category moving from niche adoption to mainstream consumer health.

What NR Does (and What It Doesn’t)

Nicotinamide riboside is a precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism, DNA repair signaling, and mitochondrial function. NAD+ levels decline with age — a well-documented phenomenon — and precursor supplementation has been studied as a means of restoring those levels in aging tissue.

The research on NR is promising but still maturing. Human trials have demonstrated that oral NR supplementation measurably raises blood NAD+ levels. Whether elevated NAD+ translates into functional health outcomes — improved metabolic markers, better cellular repair, measurable performance differences — remains an active area of investigation. The biochemical effect is real; the clinical significance for healthy adults requires more evidence.

What the Revenue Signal Actually Means

Thirty percent growth on a $100M+ revenue base is not a startup metric. It describes a product that has crossed into sustained repeat-purchaser territory — people buying it not because it’s new, but because they believe it works and plan to continue. Net income more than doubling (from an implied ~$8.5M to $17.4M) indicates that growth is not being driven by unsustainable customer acquisition spending; the unit economics are improving as the category matures.

The broader NAD+ precursor market — which includes NMN (nicotinamide mononucleotide), a competing precursor — has attracted significant retail and direct-to-consumer investment over the past three years. NR and NMN differ in their synthesis pathways to NAD+ and in their bioavailability profiles, and the debate about which is more effective in humans remains unresolved in the literature. Niagen’s growth trajectory suggests NR is holding its position in a market that briefly appeared to be consolidating around NMN.

The So What?

The longevity supplement category is often dismissed as aspirational wellness spending with thin scientific backing. Niagen’s revenue trajectory describes something more durable: a significant number of health-aware consumers are treating NAD+ precursor supplementation as a long-term protocol, not a trial purchase. The 103% net income increase confirms this is not growth driven by discounting or aggressive ad spend — it’s a margin-expanding business, which reflects genuine repeat demand.

For anyone building a longevity-oriented supplement stack, the financial signal is worth weighing alongside the incomplete clinical picture. The research on NR is real but not settled. Consult a qualified healthcare provider before starting NAD+ precursor supplementation, particularly if you have metabolic conditions or take medications that interact with cellular energy pathways.

Cited References

• Niagen Bioscience reports 30% sales growth in 2025 — Longevity.Technology
• NAD+ metabolism and its roles in cellular processes — Nature Reviews Molecular Cell Biology
• Nicotinamide riboside: research summary and evidence — Examine.com

Photo by Supplements On Demand on Pexels

Content created with AI assistance and reviewed for accuracy.